Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Candel Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "Investor Contact"
06/29/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
06/13/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Contact"
06/08/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Investor Contact"
05/23/2023 ARS Form ARS - Annual Report to Security Holders:
05/23/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
05/19/2023 8-K Investor presentation
Docs: "106 0 0 NA NA 2",
"Investor Contact"
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "Investor Contact"
05/09/2023 8-K Shareholder Nominations Pursuant to Exchange Act Rule 14a-11, Financial Statements and Exhibits  Interactive ...
05/01/2023 10-K/A Annual Report for the period ended December 31, 2022 [amend]
04/17/2023 8-K Quarterly results
03/30/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/30/2023 10-K Annual Report for the period ended December 31, 2022
03/30/2023 8-K Quarterly results
02/22/2023 8-K Regulation FD Disclosure  Interactive Data
02/09/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
12/06/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Contact"
12/06/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "R&D Day Corporate Presentation",
"R&D Day Corporate Presentation"
11/29/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Candel Therapeutics to Host Virtual R&D Day on December 6, 2022 • New clinical data to be presented from the Company’s phase 2 clinical trial of CAN-2409 in combination with anti-PD-1 agents in patients with late-stage non-small cell lung cancer. • Recent clinical data for CAN-3110 and CAN-2409 in high-grade glioma to be presented. • Scientific rationale for the recently announced collaboration with the University of Pennsylvania using Candel’s enLIGHTEN™ discovery platform to be discussed. • Premier experts and thought leaders in immunology and oncology to share perspectives on broad, potential, therapeutic combination synergies and growing opportunity for Candel’s novel viral immunotherapies. NEEDHAM, Mass., November 29, 2022 --"
11/18/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Candel Therapeutics Announces Oral Presentation of Updated Data from its Phase 1 Clinical Trial of CAN-3110 in 41 Patients with Recurrent High-Grade Glioma at the Society for Neuro-Oncology 27th Annual Meeting • CAN-3110 designed to limit replication and promote anti-tumor response to tumor cells while protecting healthy tissue • No dose-limiting toxicities observed in 41 patients with recurrent high-grade glioma • Median overall survival was 11.6 months after a single injection of CAN-3110 in patients with rHGG; one patient achieved a complete response lasting more than one year • CAN-3110 observed to activate lymphocyte-depleted tumor microenvironment in rHGG, with changes in T cell receptor repertoire associated with survival NEEDHAM, Mass., November 18, 2022..."
10/14/2022 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
09/07/2022 8-K Quarterly results
09/02/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
09/02/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
08/15/2022 EFFECT Form EFFECT - Notice of Effectiveness:
08/05/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
08/05/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/05/2022 8-K Quarterly results
Docs: "Investor Contact"
08/01/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Candel Therapeutics Appoints Three New Members to its Board of Directors"
06/06/2022 8-K Quarterly results
05/26/2022 8-K Quarterly results
05/12/2022 10-Q Quarterly Report for the period ended March 31, 2022
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy